Cargando…
Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents
The p21-activated kinase 4 (PAK4) is a member of the PAKs family. It is overexpressed in multiple tumor tissues. Pharmacological inhibition of PAK4 attenuates proliferation, migration, and invasion of cancer cells. Recent studies revealed that inhibition of PAK4 sensitizes immunotherapy which has be...
Autores principales: | Li, Yang, Lu, Qing, Xie, Chenghu, Yu, Yiming, Zhang, Ao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465411/ https://www.ncbi.nlm.nih.gov/pubmed/36105226 http://dx.doi.org/10.3389/fphar.2022.956220 |
Ejemplares similares
-
Recent advances in the development of p21-activated kinase inhibitors
por: Coleman, Natalia, et al.
Publicado: (2012) -
Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
por: Bansal, Isha, et al.
Publicado: (2023) -
Recent Advances in Nanotheranostic Agents for Tumor Microenvironment–Responsive Magnetic Resonance Imaging
por: Jin, Longhai, et al.
Publicado: (2022) -
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
por: Jain, Nem Kumar, et al.
Publicado: (2023) -
Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)